64 citations
,
July 2016 in “Journal of Immunology” Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.
January 2024 in “International Journal of Molecular Sciences” Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.
December 2025 in “Nature Communications” Blocking IL-17a can improve age-related smell loss in mice.
February 2023 in “Research Square (Research Square)” Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.
July 2025 in “International Journal of Molecular Sciences” Blocking CXCL12 can reverse hair loss and fibrosis in androgenetic alopecia.
35 citations
,
October 2013 in “Journal of Dermatological Science” VEGF165 influences hair follicle cell growth and movement through VEGFR-2 activation.
245 citations
,
April 2009 in “Circulation Research” CD133+ cells help heal diabetic ulcers by promoting blood vessel growth and activating Wnt signaling.
April 2025 in “International Journal of Molecular Sciences” New treatments for hair loss show promise with advanced therapies and better targeting.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
June 2017 in “Experimental and Therapeutic Medicine” The anti-CXCL4 antibody helps mice grow hair faster and prevents hair loss.
April 2026 in “Frontiers in Immunology” Blocking the CXCL12–CXCR4 axis may help treat hair loss in alopecia.
August 2024 in “Frontiers in Pharmacology” Antibody treatments show promise for hair loss but need more research.
112 citations
,
January 2014 in “Molecular and cellular therapies” Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.
April 2022 in “Biomedicine & Pharmacotherapy” CXCL12 protein slows down hair growth through its receptor CXCR4. Blocking this can potentially increase hair growth.
32 citations
,
February 2024 in “The Journal of Experimental Medicine” CXCL12+ fibroblasts help recruit neutrophils to fight skin infections.
June 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” ILC1-like cells can cause alopecia areata by attacking hair follicles.
December 2024 in “International Journal of Molecular Sciences” Targeting CXCL12 may help treat hair loss caused by androgens.
ILC1-like cells can independently cause alopecia areata by affecting hair follicles.
21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
3 citations
,
September 2023 in “Advanced science” A new vaccine using a porous scaffold boosts immunity and protects against the flu better than traditional methods.
5 citations
,
December 2022 in “Genes” Genetic differences affect how people respond to COVID-19.
1 citations
,
January 2013 in “Journal of Investigative Dermatology” The document concludes that stem cells and their environments are crucial for skin and hair health and have potential for medical treatments.
55 citations
,
April 2010 in “Cancer and Metastasis Reviews” TGFβ's manipulation of inflammation and immune cells affects cancer spread, suggesting new treatment strategies and biomarkers.
187 citations
,
April 2019 in “npj Regenerative Medicine” Wharton's jelly secretomes are best for promoting blood vessel growth.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
125 citations
,
August 2020 in “Frontiers in Immunology” Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
74 citations
,
May 2016 in “Current opinion in pediatrics, with evaluated MEDLINE/Current opinion in pediatrics” Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.
60 citations
,
September 2015 in “Expert Review of Clinical Immunology” Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.